AbCellera Biologics (NASDAQ:ABCL) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:05 PM.
Here’s what investors need to know about the announcement.
Earnings
AbCellera Biologics reported in-line EPS of $-0.14 versus an estimate of $-0.14.
Revenue was down $304.39 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.1 which was followed by a 1.12% drop in the share price the next day.
Here’s a look at AbCellera Biologics’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | 0 | 0.04 | -0.02 | 0.33 |
| EPS Actual | -0.1 | 0.08 | -0.02 | 0.54 |
| Revenue Estimate | 50.80M | 74.95M | 53.59M | 194.67M |
| Revenue Actual | 21.55M | 101.38M | 45.92M | 316.58M |
To track all earnings releases for AbCellera Biologics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
